Latest news
Protagonist Therapeutics, Inc. Stock 12‑Month Price Target Raised to $152.14, Implies 11% Upside - TradingViewTradingView · Thu, 06 Aug 2026 23:20:29 GMTProtagonist Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Wed, 05 Aug 2026 21:22:29 GMTProtagonist Therapeutics, Inc 2026: Revenue $213.48M, EPS $2.29— 10-Q Summary - TradingViewTradingView · Wed, 05 Aug 2026 20:26:35 GMT